323 related articles for article (PubMed ID: 29177954)
1. Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.
Jakobsen Falk I; Lund J; Gréen H; Gruber A; Alici E; Lauri B; Blimark C; Mellqvist UH; Swedin A; Forsberg K; Carlsson C; Hardling M; Ahlberg L; Lotfi K; Nahi H
Cancer Chemother Pharmacol; 2018 Jan; 81(1):183-193. PubMed ID: 29177954
[TBL] [Abstract][Full Text] [Related]
2. Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma.
Kobayashi T; Miura M; Abumiya M; Akamine Y; Ito F; Takahashi N
Med Oncol; 2019 May; 36(6):55. PubMed ID: 31089832
[TBL] [Abstract][Full Text] [Related]
3. ABCB1 variants confer susceptibility to primary open-angle glaucoma and predict individual differences to latanoprost treatment.
Liu H; Yang ZK; Li Y; Zhang WJ; Wang YT; Duan XC
Biomed Pharmacother; 2016 May; 80():115-120. PubMed ID: 27133047
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymorphisms of ABCB1.
Liang X; Shi H; Bi K; Feng S; Chen S; Zhao W; Huang X
Sci Rep; 2024 Jan; 14(1):2577. PubMed ID: 38297024
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.
Knauf W; Aldaoud A; Losem C; Mittermueller J; Neise M; Niemeier B; Harde J; Trarbach T; Potthoff K
Leuk Res; 2018 May; 68():90-97. PubMed ID: 29579627
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.
Lund J; Gruber A; Lauri B; Duru AD; Blimark C; Swedin A; Hansson M; Forsberg K; Ahlberg L; Carlsson C; Waage A; Gimsing P; Vangsted AJ; Frølund U; Holmberg E; Gahrton G; Alici E; Hardling M; Mellqvist UH; Nahi H
Cancer Med; 2018 Jun; 7(6):2256-2268. PubMed ID: 29673108
[TBL] [Abstract][Full Text] [Related]
7. Influence of ABCB1 (1236C > T, 2677G > T and 3435C > T) polymorphisms on the transport ability of P-gp-mediated sunitinib in Caco-2 cell line.
Tan DQ
Xenobiotica; 2020 Mar; 50(3):346-353. PubMed ID: 31023123
[TBL] [Abstract][Full Text] [Related]
8. Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients.
Jabir RS; Ho GF; Annuar MABA; Stanslas J
Clin Breast Cancer; 2018 Oct; 18(5):e1173-e1179. PubMed ID: 29885788
[TBL] [Abstract][Full Text] [Related]
9. Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene.
Kimchi-Sarfaty C; Marple AH; Shinar S; Kimchi AM; Scavo D; Roma MI; Kim IW; Jones A; Arora M; Gribar J; Gurwitz D; Gottesman MM
Pharmacogenomics; 2007 Jan; 8(1):29-39. PubMed ID: 17187507
[TBL] [Abstract][Full Text] [Related]
10. ABCB1 Polymorphisms and Cold Pressor Pain Responses: Opioid-Dependent Patients on Methadone Maintenance Therapy.
Zahari Z; Lee CS; Ibrahim MA; Musa N; Mohd Yasin MA; Lee YY; Tan SC; Mohamad N; Ismail R
Nurs Res; 2017; 66(2):134-144. PubMed ID: 28252574
[TBL] [Abstract][Full Text] [Related]
11. Modification of the association between paroxetine serum concentration and SERT-occupancy by ABCB1 (P-glycoprotein) polymorphisms in major depressive disorder.
Simoons M; Mulder H; Appeldoorn JTY; Risselada AJ; Schene AH; van Schaik RHN; van Roon EN; Ruhé EG
Psychiatr Genet; 2020 Feb; 30(1):19-29. PubMed ID: 31634334
[TBL] [Abstract][Full Text] [Related]
12. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients.
Genvigir FD; Salgado PC; Felipe CR; Luo EY; Alves C; Cerda A; Tedesco-Silva H; Medina-Pestana JO; Oliveira N; Rodrigues AC; Doi SQ; Hirata MH; Hirata RD
Pharmacogenet Genomics; 2016 Oct; 26(10):462-72. PubMed ID: 27434656
[TBL] [Abstract][Full Text] [Related]
13. ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients.
Björn N; Jakobsen Falk I; Vergote I; Gréen H
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):277-287. PubMed ID: 29504705
[TBL] [Abstract][Full Text] [Related]
14. ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer.
Panczyk M; Balcerczak E; Piaskowski S; Jamroziak K; Pasz-Walczak G; Mirowski M
Int J Colorectal Dis; 2009 Aug; 24(8):895-905. PubMed ID: 19415305
[TBL] [Abstract][Full Text] [Related]
15. Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia.
Hattori S; Suda A; Kishida I; Miyauchi M; Shiraishi Y; Fujibayashi M; Tsujita N; Ishii C; Ishii N; Moritani T; Taguri M; Hirayasu Y
BMC Psychiatry; 2018 Jul; 18(1):231. PubMed ID: 30016952
[TBL] [Abstract][Full Text] [Related]
16. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
Tandia M; Mhiri A; Paule B; Saffroy R; Cailliez V; Noé G; Farinotti R; Bonhomme-Faivre L
Cancer Chemother Pharmacol; 2017 Apr; 79(4):759-766. PubMed ID: 28289864
[TBL] [Abstract][Full Text] [Related]
17. GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.
Ferracini AC; Lopes-Aguiar L; Lourenço GJ; Yoshida A; Lima CSP; Sarian LO; Derchain S; Kroetz DL; Mazzola PG
Clin Transl Sci; 2021 Mar; 14(2):720-728. PubMed ID: 33326171
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.
Buda G; Ricci D; Huang CC; Favis R; Cohen N; Zhuang SH; Harousseau JL; Sonneveld P; Bladé J; Orlowski RZ
Ann Hematol; 2010 Nov; 89(11):1133-40. PubMed ID: 20532504
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Möller J; Nicklasson L; Murthy A
J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
[TBL] [Abstract][Full Text] [Related]
20. Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype.
Jakobsen Falk I; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
Br J Haematol; 2014 Dec; 167(5):671-80. PubMed ID: 25155901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
